Izvorni znanstveni članak
Survival of the patients with metastatic prostate cancer diagnosed at initial presentation: a 14-year follow-up in Karlovac General Hospital
Davorin Katušin
; Department of Urology, Karlovac General Hospital, Karlovac, Croatia
Slavica Klarica-Vučinić
; Department of Urology, Karlovac General Hospital, Karlovac, Croatia
Miljenko Križ
; Department of Urology, Karlovac General Hospital, Karlovac, Croatia
Željko Poka
; Department of Urology, Karlovac General Hospital, Karlovac, Croatia
Jasminka Sušanj
; Department of Urology, Karlovac General Hospital, Karlovac, Croatia
Doroteja Janković
; Department of Urology, Karlovac General Hospital, Karlovac, Croatia
Sažetak
Despite a very favorable stage migration, there are still patients with bone and/or nodal metastasis at the time of initial diagnosis of prostate cancer (CaP). The incidence of these patients varies significantly from country to country depending on whether or not programs for CaP screening are implemented in their health policy. In contrast to vast interest for prognosis of patients who develop metastasis after radical treatment of presumed localised CaP, there are only a few studies in recent literature analyzing survival of patients diagnosed with metastasis at initial presentation. In our study, we analyzed 128 patients with CaP in whom metastasis were assessed at the time of diagnosis. Ninety-five (74.2%) of all metastatic patients had bone metastasis (T1-4N0M1), 17 (13.3%) had metastasis in lymph nodes (T1-4N1M0) and in 16 (12.5%) patients metastasis were assessed both in bones and lymph nodes (T1-4N1M1). Patients with both bone and nodal metastasis (T1-4N1M1) had a significantly higher average PSA value and significantly higher average Gleason score. The median time to progression for all pateints was 12 (1-86) months while the median survival time was 18 (1-135) months. The tumor-specific survival of the patients with both bone and nodal metastasis (T1-4N1M1) was significantly worse than the survival of the patients with only bone or only nodal involvement.
In conclusion, despite the introduction of new hormonal and cytotoxic agents and strategies, prognosis for patients with metastatic prostate cancer remains poor, especially if they initially present with both bone and nodal metastasis.
Ključne riječi
prostate cancer; metastasis; survival; prognosis
Hrčak ID:
278778
URI
Datum izdavanja:
30.11.2009.
Posjeta: 669 *